Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes : rationale and design of the ODYSSEY Outcomes trial

Schwartz, Gregory G.
Bessac, Laurence
Berdan, Lisa G.
Bhatt, Deepak L.
Bittner, Vera
Diaz, Rafael
Goodman, Shaun G.
Hanotin, Corinne
Harrington, Robert A.
Jukema, J. Wouter
Mahaffey, Kenneth
Moryusef, Angèle
Pordy, Robert
Roe, Matthew T.
Rorick, Tyrus
Sasiela, William J.
Shirodaria, Cheerag
Szarek, Michael
Tamby, Jean-François
Tricoci, Pierluigi
White, Harvey
Zeiher, Andreas Michael
Steg, P. Gabriel

August 2014

Background: Following acute coronary syndrome (ACS), the risk for future cardiovascular events is hi...

(OSLER), and The Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy (ODYSSEY

August 2016

PCSK9 inhibitors on the right track of reducing cardiovascular events Mohamed Hassan* Proprotein con...

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

Cannon, Christopher P.
Cariou, Bertrand
Blom, Dirk
McKenney, James M.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh
Colhoun, Helen M.

June 2015

Aims To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of al...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, Helen M.
Robinson, Jennifer G.
Farnier, Michel
Cariou, Bertrand
Blom, Dirk
Kereiakes, Dean J.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh

January 2014

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PC...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, Helen M.
Robinson, Jennifer G.
Farnier, Michel
Cariou, Bertrand
Blom, Dirk
Kereiakes, Dean J.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh

January 2014

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PC...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, Helen M.
Robinson, Jennifer G.
Farnier, Michel
Cariou, Bertrand
Blom, Dirk
Kereiakes, Dean J.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh

January 2014

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PC...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, Helen M.
Robinson, Jennifer G.
Farnier, Michel
Cariou, Bertrand
Blom, Dirk
Kereiakes, Dean J.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh

January 2014

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PC...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, Helen M.
Robinson, Jennifer G.
Farnier, Michel
Cariou, Bertrand
Blom, Dirk
Kereiakes, Dean J.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh

January 2014

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PC...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, Helen M.
Robinson, Jennifer G.
Farnier, Michel
Cariou, Bertrand
Blom, Dirk
Kereiakes, Dean J.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh

January 2014

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PC...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, Helen M.
Robinson, Jennifer G.
Farnier, Michel
Cariou, Bertrand
Blom, Dirk
Kereiakes, Dean J.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh

January 2014

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PC...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, Helen M.
Robinson, Jennifer G.
Farnier, Michel
Cariou, Bertrand
Blom, Dirk
Kereiakes, Dean J.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh

January 2014

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PC...

Focus on alirocumab: a PCSK9 antibody to treat hypercholesterolemia Autori

Devito, F
Zito, A
Ricci, G
Carbonara, R
Dentamaro, I
Cortese, F
Carbonara, S
Ciccone, Mm

January 2015

Statin treatment represents the gold standard in the reduction of low-density lipoprotein cholestero...

Focus on alirocumab: a PCSK9 antibody to treat hypercholesterolemia Autori

Devito, F
Zito, A
Ricci, G
Carbonara, R
Dentamaro, I
Cortese, F
Carbonara, S
Ciccone, Mm

January 2015

Statin treatment represents the gold standard in the reduction of low-density lipoprotein cholestero...

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study

Chang-Wook Nam
Dong-Soo Kim
Jianyong Li
Marie T. Baccara-Dinet
Ivy Li
Ji-Hyun Kim
Chong-Jin Kim

November 2019

Background/Aims Efficacy and safety data of alirocumab, a fully human monoclonal antibody to proprot...

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes : rationale and design of the ODYSSEY Outcomes trial

Schwartz, Gregory G.
Bessac, Laurence
Berdan, Lisa G.
Bhatt, Deepak L.
Bittner, Vera
Diaz, Rafael
Goodman, Shaun G.
Hanotin, Corinne
Harrington, Robert A.
Jukema, J. Wouter
Mahaffey, Kenneth
Moryusef, Angèle
Pordy, Robert
Roe, Matthew T.
Rorick, Tyrus
Sasiela, William J.
Shirodaria, Cheerag
Szarek, Michael
Tamby, Jean-François
Tricoci, Pierluigi
White, Harvey
Zeiher, Andreas M.
Steg, P. Gabriel

August 2014

Background: Following acute coronary syndrome (ACS), the risk for future cardiovascular events is hi...

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes : rationale and design of the ODYSSEY Outcomes trial

Schwartz, Gregory G.
Bessac, Laurence
Berdan, Lisa G.
Bhatt, Deepak L.
Bittner, Vera
Diaz, Rafael
Goodman, Shaun G.
Hanotin, Corinne
Harrington, Robert A.
Jukema, J. Wouter
Mahaffey, Kenneth
Moryusef, Angèle
Pordy, Robert
Roe, Matthew T.
Rorick, Tyrus
Sasiela, William J.
Shirodaria, Cheerag
Szarek, Michael
Tamby, Jean-François
Tricoci, Pierluigi
White, Harvey
Zeiher, Andreas Michael
Steg, P. Gabriel

August 2014

Background: Following acute coronary syndrome (ACS), the risk for future cardiovascular events is hi...

(OSLER), and The Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy (ODYSSEY

August 2016

PCSK9 inhibitors on the right track of reducing cardiovascular events Mohamed Hassan* Proprotein con...

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

Cannon, Christopher P.
Cariou, Bertrand
Blom, Dirk
McKenney, James M.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh
Colhoun, Helen M.

June 2015

Aims To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of al...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, Helen M.
Robinson, Jennifer G.
Farnier, Michel
Cariou, Bertrand
Blom, Dirk
Kereiakes, Dean J.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh

January 2014

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PC...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, Helen M.
Robinson, Jennifer G.
Farnier, Michel
Cariou, Bertrand
Blom, Dirk
Kereiakes, Dean J.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh

January 2014

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PC...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, Helen M.
Robinson, Jennifer G.
Farnier, Michel
Cariou, Bertrand
Blom, Dirk
Kereiakes, Dean J.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh

January 2014

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PC...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, Helen M.
Robinson, Jennifer G.
Farnier, Michel
Cariou, Bertrand
Blom, Dirk
Kereiakes, Dean J.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh

January 2014

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PC...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, Helen M.
Robinson, Jennifer G.
Farnier, Michel
Cariou, Bertrand
Blom, Dirk
Kereiakes, Dean J.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh

January 2014

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PC...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, Helen M.
Robinson, Jennifer G.
Farnier, Michel
Cariou, Bertrand
Blom, Dirk
Kereiakes, Dean J.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh

January 2014

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PC...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, Helen M.
Robinson, Jennifer G.
Farnier, Michel
Cariou, Bertrand
Blom, Dirk
Kereiakes, Dean J.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh

January 2014

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PC...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Colhoun, Helen M.
Robinson, Jennifer G.
Farnier, Michel
Cariou, Bertrand
Blom, Dirk
Kereiakes, Dean J.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh

January 2014

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 (PC...

Focus on alirocumab: a PCSK9 antibody to treat hypercholesterolemia Autori

Devito, F
Zito, A
Ricci, G
Carbonara, R
Dentamaro, I
Cortese, F
Carbonara, S
Ciccone, Mm

January 2015

Statin treatment represents the gold standard in the reduction of low-density lipoprotein cholestero...

Focus on alirocumab: a PCSK9 antibody to treat hypercholesterolemia Autori

Devito, F
Zito, A
Ricci, G
Carbonara, R
Dentamaro, I
Cortese, F
Carbonara, S
Ciccone, Mm

January 2015

Statin treatment represents the gold standard in the reduction of low-density lipoprotein cholestero...

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study

Chang-Wook Nam
Dong-Soo Kim
Jianyong Li
Marie T. Baccara-Dinet
Ivy Li
Ji-Hyun Kim
Chong-Jin Kim

November 2019

Background/Aims Efficacy and safety data of alirocumab, a fully human monoclonal antibody to proprot...

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes : rationale and design of the ODYSSEY Outcomes trial

Schwartz, Gregory G.
Bessac, Laurence
Berdan, Lisa G.
Bhatt, Deepak L.
Bittner, Vera
Diaz, Rafael
Goodman, Shaun G.
Hanotin, Corinne
Harrington, Robert A.
Jukema, J. Wouter
Mahaffey, Kenneth
Moryusef, Angèle
Pordy, Robert
Roe, Matthew T.
Rorick, Tyrus
Sasiela, William J.
Shirodaria, Cheerag
Szarek, Michael
Tamby, Jean-François
Tricoci, Pierluigi
White, Harvey
Zeiher, Andreas M.
Steg, P. Gabriel

August 2014

Background: Following acute coronary syndrome (ACS), the risk for future cardiovascular events is hi...

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes : rationale and design of the ODYSSEY Outcomes trial

Schwartz, Gregory G.
Bessac, Laurence
Berdan, Lisa G.
Bhatt, Deepak L.
Bittner, Vera
Diaz, Rafael
Goodman, Shaun G.
Hanotin, Corinne
Harrington, Robert A.
Jukema, J. Wouter
Mahaffey, Kenneth
Moryusef, Angèle
Pordy, Robert
Roe, Matthew T.
Rorick, Tyrus
Sasiela, William J.
Shirodaria, Cheerag
Szarek, Michael
Tamby, Jean-François
Tricoci, Pierluigi
White, Harvey
Zeiher, Andreas Michael
Steg, P. Gabriel

August 2014

Background: Following acute coronary syndrome (ACS), the risk for future cardiovascular events is hi...

(OSLER), and The Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy (ODYSSEY

August 2016

PCSK9 inhibitors on the right track of reducing cardiovascular events Mohamed Hassan* Proprotein con...

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

Cannon, Christopher P.
Cariou, Bertrand
Blom, Dirk
McKenney, James M.
Lorenzato, Christelle
Pordy, Robert
Chaudhari, Umesh
Colhoun, Helen M.

June 2015

Aims To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of al...

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Abstract

Extracted data

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins:rationale and design of the ODYSSEY COMBO I and II trials

Abstract

Extracted data

Related items

Related items